Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

European Quality Improvement Programme for Acute Coronary Syndromes (EQUIP-ACS)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2008 by Royal Brompton & Harefield NHS Foundation Trust.
Recruitment status was:  Recruiting
Sponsor:
Collaborators:
Uppsala University
GlaxoSmithKline
Information provided by:
Royal Brompton & Harefield NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT00716430
First received: July 11, 2008
Last updated: July 15, 2008
Last verified: July 2008
  Purpose
The main hypothesis to be tested is that the use of a quality improvement programme will lead to measurable improvements in the management of care and use of evidence based treatments for patients presenting to hospital with non-ST elevation acute coronary syndromes.

Condition Intervention
Acute Coronary Syndrome
Behavioral: Quality Improvement Programme

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Improving the Management of Non-ST Elevation Acute Coronary Syndrome: Systematic Evaluation of a Quality Improvement Programme

Further study details as provided by Royal Brompton & Harefield NHS Foundation Trust:

Primary Outcome Measures:
  • Composite of 7 outcome measures to assess aggregate potential for improvement in care using the QI programme:1:risk stratification within 24 hrs, 2:early coronary angiography, 3:anticoagulation, 4:beta-blockers, 5:statins, 6:ACE-inhibitors, 7:Clopidogrel [ Time Frame: 10 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical outcomes at discharge including death and myocardial infarction [ Time Frame: 10 months ] [ Designated as safety issue: No ]
  • Estimated costs of care for patients [ Time Frame: 10 months ] [ Designated as safety issue: No ]
  • Estimated costs and economic evaluation of potential cost-effectiveness of QI programme [ Time Frame: 10 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 3500
Study Start Date: August 2007
Estimated Study Completion Date: February 2009
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: QI
Quality Improvement Centres
Behavioral: Quality Improvement Programme
Quality Improvement training programme
No Intervention: Non-QI
No Quality Improvement Programme

  Eligibility

Ages Eligible for Study:   up to 80 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients with a good clinical history of ACS and at least one of the following:

  • New or transient ST or T wave changes on the ECG consistent with acute myocardial ischaemia
  • Elevation of troponin or other cardiac markers to levels indicative of myocardial necrosis according to local laboratory values

Exclusion Criteria:

  • Evidence of persistent ST elevation on the ECG
  • Use of early reperfusion therapy
  • Patients >80 years
  • Patients transferred from another hospital
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00716430

Locations
France
Centre Hospitalier de la region d'Annecy
Annecy, France
Centre Hospitalier de Chambery
Chambery, France
Cardiology dept. B, CHU Hopital G. Montpied
Clermont Ferrand, France
CHU de Grenoble
Grenoble, France
Centre Hospitalier de Riom Guy Thomas
Riom, France
Hopitaux Drome Nord de Romans-sur-Isere
Romans-sur-Isere, France
Centre Hospitalier d'Ussel
Ussel, France
Centre Hospitalier Pierre Bazin
Voiron, France
Italy
Ospedale M. Bufalini
Cesena, Italy
Ospedale Morgagni-Pierantoni
Forli, Italy
Ospedale di Livorno
Livorno, Italy
Ospedale Generale Provinciale di Macerata
Macerata, Italy
Ospedale Civile di Mirano
Mirano, Italy
Poland
Szpital w Ciechanowie
Ciechanow, Poland
Szpital Zachodni
Grodzisk Mazowiecki, Poland
Szpital w Grojcu
Grojec, Poland
Swietofrzyskie Centrum Chorob Serca
Kielce, Poland
Szpital w Plocku
Plock, Poland
Radomski Szpital Specjalistyczny
Radom, Poland
Szpital Specjalistyczny SPZOZ w Radom
Radom, Poland
Szpital w Siedlcach
Siedlce, Poland
SP CSK- Medical University of Warsaw
Warsaw, Poland
Szpital we Wloclawku
Wloclawek, Poland
Spain
Hospital Universitario Germans Trias
Badalona, Spain
Hospital del Mar
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Josep Trueta
Girona, Spain
Hospital Universitario Joan XXIII
Tarragona, Spain
Hospital de Terrassa
Terrassa-Barcelona, Spain
Hospital de Tortosa Virgen de la Cinta
Tortosa, Spain
United Kingdom
Antrim Area Hospital
Antrim, United Kingdom
Barnet General Hospital
Barnet, United Kingdom
Basildon Hospital
Essex, United Kingdom
Warwick Hospital
Warwick, United Kingdom
Royal Albert Edward Infirmary
Wigan, United Kingdom
Yeovil District Hospital
Yeovil, United Kingdom
York District Hospital
York, United Kingdom
Sponsors and Collaborators
Royal Brompton & Harefield NHS Foundation Trust
Uppsala University
GlaxoSmithKline
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr Marcus Flather, Royal Brompton Hospital
ClinicalTrials.gov Identifier: NCT00716430     History of Changes
Other Study ID Numbers: EQUIP-ACS 1 
Study First Received: July 11, 2008
Last Updated: July 15, 2008
Health Authority: United Kingdom: Research Ethics Committee
France: Comite d'Ethique des Centres d'Investigation Clinique
Spain: Comité Ético de Investigación Clínica
Italy: National Ethics Committee
Poland: Komisja Bioetyczna

Keywords provided by Royal Brompton & Harefield NHS Foundation Trust:
acute coronary syndromes
quality improvement

Additional relevant MeSH terms:
Syndrome
Acute Coronary Syndrome
Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on December 02, 2016